April 22, 2025
Medical Affairs Is Stepping Into the Future
The energy was palpable at the 2025 Medical Affairs Professional Society (MAPS) Global Annual Meeting. Conversations were expansive, workshops immersive, and the questions being asked were less about what Medical Affairs can do and more about how it must evolve to meet the future.
January 29, 2025
Connect, Communicate, and Conquer 2025
October 21, 2024
The Power of Key Business Questions
In our biopharma world, we frequently hear the term “Key Business Questions (KBQs).” And while it’s often thrown around as a buzzword (or buzz phrase, in this case), it has quite a bit of practical value when its full depth is explored.
September 24, 2024
The Underappreciated Value of New Product Planning
August 21, 2024
Biopharma Annual Planning Success: Close Your Rings Year-Round
How do we think about biopharma annual planning differently? The analogy I will draw on is fitness trackers and apps—built for mindfulness and exercise—these devices and apps create a habit for daily (weekly, monthly, etc.) self-challenges.
July 22, 2024
The Power of Target Product Profiles: Three Case Studies
In the biopharma industry, the Target Product Profile (TPP) is a critical tool for guiding the development and commercialization of new drugs.
June 25, 2024
Unlocking Success: The Power of Target Product Profiles
In the ever-evolving biopharma landscape, success hinges not just on innovation but also on a clear roadmap guiding clinical and commercial development.
April 23, 2024
Governance: The Glue to a Successful Launch
At the core of every successful launch lies a meticulously crafted plan, a robust governance structure, and expert management of its execution.
March 26, 2024
Your Biopharma Data Needs a Strategy
In the not-so-distant past, physician prescribing data was essentially a commodity with limited breadth or depth for the purposes of drug development and commercialization. Two primary third-party providers aggregated data from essentially the same sources.
January 24, 2024
Juggling Geographic Commercialization Priorities
Commercializing a pharmaceutical asset in one country is hard enough. Doing it on a global scale, with multiple country differences, is exponentially more difficult.